Literature DB >> 9253112

Differential effect of erythropoietin and GM-CSF on megakaryocytopoiesis from primitive bone marrow cells in serum-free conditions.

J E Cardier1, C L Erickson-Miller, M J Murphy.   

Abstract

In this study we have explored the effect of recombinant human erythropoietin (EPO) and recombinant murine GM-CSF on megakaryocyte progenitors (colony forming units-megakaryocyte [CFU-Mk]) using a serum-free fibrin clot assay and enriched primitive hematopoietic progenitors of marrow cells from day 4 post-5-fluorouracil-treated mice. We have monitored the production of high proliferative potential-colony forming cells ([HPP-CFC]; compact colonies, > 0.5 mm) and studied their relationship to CFU-Mk formation. EPO induced the formation of small numbers of megakaryocyte colonies, but acted together with the megakaryocyte-stimulating factors, stem cell factor (SCF) and interleukin (IL-3), to augment the size of CFU-Mk (colonies with > 50 megakaryocytes/colony). A strong correlation between the number of CFU-Mk and HPP-CFC formation from 5-fluorouracil bone marrow cells was observed when these cells were stimulated with EPO in the presence of SCF and IL-3. On the other hand, GM-CSF alone had no effect on megakaryocyte colony formation. Moreover, GM-CSF in the presence of SCF and IL-3 potentiates the HPP-CFC formation (i.e., an increase of 3.1-fold compared to the effect induced by SCF+IL-3) with strong inhibitory effects on the number and size of megakaryocyte colonies. Although several studies suggest that EPO and GM-CSF can stimulate megakaryocytopoiesis, our results indicate that neither EPO nor GM-CSF alone are sufficient to stimulate primitive progenitors committed to the megakaryocyte lineage. The fact that EPO can exert a strong effect on the size of CFU-Mk induced by SCF/IL-3 suggests that only those megakaryocyte progenitors previously stimulated by other megakaryocyte stimulating factors are able to respond to EPO. These findings may explain the physiological and clinical observations in which high levels of EPO are often associated with thrombocytosis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9253112     DOI: 10.1002/stem.150286

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  8 in total

1.  EPO-dependent activation of PI3K/Akt/FoxO3a signalling mediates neuroprotection in in vitro and in vivo models of Parkinson's disease.

Authors:  Yu Jia; Shi-Jing Mo; Qi-Qi Feng; Ma-Li Zhan; Li-Si OuYang; Jia-Chang Chen; Yu-Xin Ma; Jia-Jia Wu; Wan-Long Lei
Journal:  J Mol Neurosci       Date:  2014-01-04       Impact factor: 3.444

2.  Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients.

Authors:  Alexander J Thompson; Paul J Clark; Abanish Singh; Dongliang Ge; Jacques Fellay; Mingfu Zhu; Qianqian Zhu; Thomas J Urban; Keyur Patel; Hans L Tillmann; Susanna Naggie; Nezam H Afdhal; Ira M Jacobson; Rafael Esteban; Fred Poordad; Eric J Lawitz; Jonathan McCone; Mitchell L Shiffman; Greg W Galler; John W King; Paul Y Kwo; Kevin V Shianna; Stephanie Noviello; Lisa D Pedicone; Clifford A Brass; Janice K Albrecht; Mark S Sulkowski; David B Goldstein; John G McHutchison; Andrew J Muir
Journal:  J Hepatol       Date:  2011-05-20       Impact factor: 25.083

3.  Reduced ITPase activity and favorable IL28B genetic variant protect against ribavirin-induced anemia in interferon-free regimens.

Authors:  Aparna Vasanthakumar; Justin W Davis; Manal Abunimeh; Jonas Söderholm; Jiuhong Zha; Emily O Dumas; Daniel E Cohen; Jeffrey F Waring; Martin Lagging
Journal:  PLoS One       Date:  2018-05-31       Impact factor: 3.240

4.  Severe thrombocytosis and anemia associated with celiac disease in a young female patient: a case report.

Authors:  Wieland Voigt; Karin Jordan; Christoph Sippel; Mroawan Amoury; Hans-Joachim Schmoll; Hans H Wolf
Journal:  J Med Case Rep       Date:  2008-04-01

5.  ITPA Polymorphisms Are Associated with Hematological Side Effects during Antiviral Therapy for Chronic HCV Infection.

Authors:  Raoel Maan; Adriaan J van der Meer; Willem Pieter Brouwer; Elisabeth P C Plompen; Milan J Sonneveld; Robert Roomer; Annemiek A van der Eijk; Zwier M A Groothuismink; Bettina E Hansen; Bart J Veldt; Harry L A Janssen; Andre Boonstra; Robert J de Knegt
Journal:  PLoS One       Date:  2015-10-06       Impact factor: 3.240

6.  Association between IPTA gene polymorphisms and hematological abnormalities in hepatitis C virus-infected patients receiving combination therapy.

Authors:  Jow Jyh Hwang; Ching Chu Lo; Chien Hung Lin; Hsu Sheng Cheng; I Wen Hung; Wan Ju Tsai; Chien Hui Hung
Journal:  Gut Liver       Date:  2015-03       Impact factor: 4.519

7.  The ITPA and C20orf194 Polymorphisms and Hematological Changes During Treatment With Pegylated-Interferon Plus Ribavirin in Patients With Chronic Hepatitis C.

Authors:  Mohammad Pouryasin; Maryam Keshvari; Heidar Sharafi; Seyed Moayed Alavian; Bita Behnava; Seyed Ehsan Alavian; Ali Pouryasin
Journal:  Hepat Mon       Date:  2016-02-20       Impact factor: 0.660

8.  Myeloproliferative Neoplasm or Reactive Process? A Rare Case of Acute Myeloid Leukemia and Transient Posttreatment Megakaryocytic Hyperplasia with JAK-2 Mutation.

Authors:  Steven Wang; Jie Yan; Guangde Zhou; Rebecca Heintzelman; J Steve Hou
Journal:  Case Rep Hematol       Date:  2016-09-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.